Cutaneous human papillomaviruses (HPVs) are a heterogeneous, nonmonophyletic assembly, comprising about 50 characterized types and at least 133 isolates putatively representing new types. Their natural history of infection and potential association with nonmelanoma skin cancer are not well understood. Several PCR systems have been developed that amplify a broad spectrum of cutaneous HPVs. However, amplicon genotyping by sequencing or reverse line blot assays are complex and not well suited for high-throughput analyses. We developed a novel multiplex cutaneous papillomavirus genotyping (McPG) assay for 38 defined and 20 putative cutaneous HPVs of the beta, gamma, mu, and nu genera. Viral DNA was amplified by the use of a modified single-tube nested "hanging-droplet" FAP PCR. The amplifiable papillomavirus (PV) spectrum was enlarged by the use of 9 outer and 13 inner primers. Biotinylated PCR products were hybridized to type-specific oligonucleotide probes coupled to fluorescence-labeled polystyrene beads and analyzed using Luminex technology. Analytical sensitivity was analyzed for 38 defined HPVs and was <100 genome copies for all types. Integrated ␤-globin primers allow for simultaneous DNA quality control. McPG is characterized by high reproducibility ‫؍(‬ 0.84, 95% confidence interval ‫؍‬ 0.79 to 0.88), good concordance with the original nested FAP PCR, followed by sequencing (70.2% complete or partial agreement) when 322 skin biopsy DNA samples were analyzed, and improved ability to detect multiple infections (on average 2.5 HPV types per HPV-positive sample compared to 1.7 HPV types with nested FAP-PCR). In conclusion, McPG is a powerful tool for genotyping multiple cutaneous HPVs in a high-throughput format and is thus suitable for large-scale epidemiological studies.
Papillomaviruses (PVs) are small, nonenveloped, doublestranded DNA viruses that can infect mucosal or cutaneous epithelia. At least 189 distinct PV types, 151 of them isolated from humans, have been completely described (5) . In addition, about 130 sequence fragments coding for the major capsid protein L1 (FA amplicons) have been isolated representing putatively new cutaneous human PV (HPV) types (12) . Based on their L1 nucleotide sequences, PVs are phylogenetically classified in genera (sharing Ͻ60% sequence identity), species (60 to 70% sequence identity), and types (70 to 90% sequence identity) (10) . Hitherto-known HPVs belong either to the alpha genus (including both mucosal and cutaneous types), or to the beta, gamma, mu, or nu genera (including mainly cutaneous types).
High-risk HPVs from the alpha genus, most importantly HPV16, infect the genital and oral mucosa and are well-established causes of cervical cancer (11, 38) . They are also found with lower frequency in other anogenital and some oropharyngeal carcinomas, while the low-risk types (mainly HPV6 and HPV11) are associated with benign genital and oral warts (38) . Cutaneous HPVs from the alpha (e.g., HPV2 and HPV3), gamma (e.g., HPV4), mu (HPV1 and HPV63), and nu (HPV41) genera cause common and flat skin warts (20) . In addition, cutaneous HPVs, especially those belonging to the beta genus, are controversially discussed to be involved in the development of nonmelanoma skin cancer (NMSC), comprising mostly basal cell carcinoma and squamous cell carcinoma (SCC).
A broad spectrum of predominantly beta PVs is found in high copy numbers (100 to 300 copies per cell equivalent) in benign and NMSC lesions, as well as in hair bulbs from plucked eyebrows of patients with the rare inherited disease epidermodysplasia verruciformis (EV) (9, 24, 25) . These PVs are also frequently found in NMSC and the perilesional skin of immunocompetent and immunosuppressed non-EV patients, albeit in very low copy numbers (usually below one copy per cell) (36) . For beta PVs, it has been shown that the viruses are transcriptionally active in benign and malignant lesions of EV patients (17, 37) and also in actinic keratosis and in SCCs of immunosuppressed non-EV patients (7, 26) . Furthermore, some natural and transgenic animal models, as well as cell culture in vitro experiments, provide evidence for an oncogenic potential of cutaneous HPVs (reviewed in references 1 and 23). However, not every tumor cell contains an HPV genome, and viral DNA is also highly prevalent in healthy skin and plucked eyebrow hairs of the normal population (23) . Unlike HPV16 and HPV18 in cervical cancer, there is no predominant cutaneous HPV in NMSCs.
To investigate the potential association of cutaneous HPVs with NMSC and the largely unknown natural history of infections, several standard (6, 8, 13, 16, (31) (32) (33) and nested (3, 4, 15, 18, 19) PCRs have been developed to amplify a broad but limited spectrum of cutaneous HPVs. These PCRs use consensus, degenerate, or type-specific primers or a combination of primer pairs mostly targeting the L1 open reading frame (ORF) and differ in the number of detectable HPV types, in the target sequence to be amplified, in the product length, and in analytical sensitivity. Thus, often only PVs of a certain genus (e.g., beta PVs) or even a fraction of types within a genus are amplified. The detection limit of the different PCR systems varies between 1 and 100,000 PV genome copies per reaction. Very high analytical sensitivities of 1 to 10 PV genome copies are featured by the single-round PCR, as well as by the nested PCR developed by Forslund et al. (13, 15) and the type-specific beta genus multiplex PCR of Gheit et al. (16) . The latter also has the advantage of an integrated ␤-globin PCR as internal DNA and PCR quality control.
Most of the methods for PCR amplicon genotyping, such as sequencing (13, 15) , reverse line blot (RLB) (6), reverse hybridization assay (RHA) (8) , or the chip-based APEX system (16) , are rather complex and not well suited for high-throughput analyses. Sequencing, in particular, is limited to few HPVs and frequently underestimates multiple infections. In contrast, bead-based HPVs genotyping assays are better suited for highthroughput analyses, such as the multiplex HPV genotyping (MPG) assay developed by Schmitt et al. (27, 29, 30 ) that allows the simultaneous detection of all known mucosal alpha HPVs in about 1,000 DNA samples per week.
Based on the assay conditions of MPG, we developed multiplex cutaneous papillomavirus genotyping (McPG) for the detection of all hitherto known 38 beta, gamma, mu, and nu HPVs, as well as 20 FA amplicons. For viral DNA amplification, we used the highly sensitive nested "hanging-droplet" FAP-PCR (15) . To enlarge the spectrum of detectable HPVs to beta, gamma, mu, and nu PVs and to allow for a homogeneously sensitive amplification, a total of 18 additional, socalled McPG primers (four outer forward, three outer reverse, and eleven inner reverse primers) were included in the PCR. For genotyping, biotinylated PCR products were hybridized to type-specific oligonucleotide probes coupled to fluorescencelabeled Luminex beads. McPG was validated by reanalyzing 322 clinical samples previously genotyped by the original nested FAP PCR and subsequent sequencing.
MATERIALS AND METHODS
Primer design. Nucleotide sequences of the L1 open reading frame (ORF) of all 38 completely described HPV genotypes belonging to beta, gamma, mu, and nu genera of 133 FA fragments and 45 FA subtypes were aligned with the online tool EMBL-EBI CLUSTAL W (21) and the computer software Se-Al Sequence Alignment Editor v2.0. In total, four outer forward, three outer reverse, and eleven inner reverse primers were designed targeting the same region of the L1 ORF as the original FAP primers FAP59, FAP64 (13) , and FAP6319R (15), respectively (see Table S1 in the supplemental material). All novel primers contain degenerated nucleotide positions and are identical in length. Each of the 216 L1 sequences was covered by at least one primer showing less than four mismatches. The original inner forward primer FAP6085F was biotinylated. For simultaneous amplification of a fragment of the ␤-globin gene, the primers MS 3 and 5Ј biotinylated MS 10 (29) were used. All primers were synthesized by Invitrogen (Karlsruhe, Germany). The general applicability of the new primer set was evaluated by PCR on individual bacterial colonies (colony PCR) transformed with plasmids containing either complete HPV genomes, sequences of the corresponding L1 ORF, or FA fragments. The McPG primers were able to amplify the PCR products of all tested 38 HPV types as well as 20 FA fragments, as determined by gel electrophoresis (data not shown) and subsequent genotyping by McPG (Table 1) .
Probe design. The aligned DNA sequences of the HPV L1 ORF, FA fragments, and FA subtypes were reviewed manually to identify a region characterized by high degree of sequence diversity. A hypervariable loop region located next to the inner reverse primer was identified and used as target sequence for the type-specific probes. Type-specific probes for 38 HPV types and 20 FA fragments were designed as described previously (27) . Briefly, all probes were designed to completely match their corresponding HPV genotype or FA amplicon and to exhibit at least three mismatches distributed across the probe sequence with the ϳ480-bp outer primer product of all other FA amplicons and cutaneous HPVs, including alpha PVs and bovine papillomavirus type 3, which served as specificity controls. The design of the ␤-globin probe is described elsewhere (29) . All type-specific probes (see Table S2 in the supplemental material) were synthesized by MWG-Biotech AG (Ebersberg, Germany).
Nested "hanging droplet" FAP PCR. The nested "hanging-droplet" FAP PCR amplifying an 235-bp fragment of the viral L1 ORF was performed as previously described (15) M in 50 l) of each inner primer (one 5Ј biotinylated forward and twelve reverse) was pipetted in the lid of the reaction tube. The PCRs took place in a MasterCycler (Eppendorf) programmed for block temperature and for the first reaction without heated lid. A 15-min denaturation step at 95°C was followed by 25 cycles, each consisting of a denaturation step at 94°C for 1.5 min, an annealing step at 50°C for 1.5 min, and an elongation step at 72°C for 1.5 min. Afterward, the "hanging droplet" was incorporated in the reaction mixture (final volume, 50 l) by centrifugation for 20 s at 6,000 rpm using a minicentrifuge (Labnet International, Inc.). The second reaction was performed using the same temperature parameters as for the first reaction but with heated lid and 45 cycles instead of 25. The preparation of all PCR mixtures as well as the addition of the samples were performed under a sterile hood in a room designated exclusively for diagnostic PCR experiments and only DNase-and RNase-free low-retention tubes (neoLab Migge GmbH, Heidelberg, Germany) and sterile filter tips (Starlab GmbH, Ahrensburg, Germany) were used.
Each PCR experiment included several samples lacking template DNA as contamination controls, one sample with an HPV reference plasmid (1,000 copies), and one sample with 100 ng of HP DNA as positive controls for HPV and ␤-globin amplification, respectively. No evidence for contamination was observed in the experiments described here.
Colony PCR. For colony PCR, DNA from DH5␣ bacteria, transformed by high-copy-number plasmids containing the whole viral genome, the HPV L1 ORF or a FA fragment was applied as a template in a single-round PCR using only the inner or the outer primer pair of the nested PCR. Portions (5 l) of the PCR product were analyzed by electrophoresis, together with 5 l of SmartLadder DNA quantification marker (Eurogentec, Seraing, Belgium) on a 2% agarose gel containing ethidium bromide (0.75 mg/liter). DNA bands were visualized by UV light and identified by size determination.
Plasmid clones. To evaluate the general applicability, specificity, sensitivity, and reproducibility of the McPG method, plasmids containing the whole HPV genome, the complete L1 ORF, or the FA fragment were used. Plasmids containing the complete genome were preferred. In cases where the cloning site is located within the outer primer product sequence, pGEX-HPV L1-tag constructs (22) were used.
Analytical sensitivity was determined for plasmid clones of all described HPV types of beta, gamma, mu, and nu genera ( Table 2) . Plasmid DNA preparations were quantified by using NanoDrop ND-1000 (NanoDrop Technologies, Wilmington, DE). Copy numbers were determined on the basis of the molecular weights of each of the plasmids. Tenfold endpoint dilution series were prepared in 20 l of water containing 100 ng of HP DNA/l. containing 1000, 100, 10, and 1 plasmid copies were applied as a template in the PCR. Dilution series were performed once; however, for four HPV types (HPV1, HPV4, HPV8, and HPV41) two to three replicates of each dilution were prepared and assayed independently. Clinical samples and pooled HPV results. Extracted DNA samples (n ϭ 342), stored at Ϫ20°C, were blindly selected from a hospital-based casecontrol study of NMSCs and premalignant and benign skin lesions (14) . Among this selection, DNA samples were obtained from 171 patients with cutaneous SCC (n ϭ 11), basal cell carcinoma (n ϭ 72), actinic keratoses (n ϭ 29), and benign lesions consisting of seborrhoeic keratoses (n ϭ 39) and other benign lesions (n ϭ 20). In addition, a control DNA sample from a biopsy specimen of healthy skin was obtained for all patients. All of the DNA samples had been pretested by three different laboratories using routine cutaneous HPV detection methods, including single-round PCR with FAP primers (13) and single-tube, nested "hanging-droplet" FAP PCR (15) , both with subsequent sequencing of PCR products for identification of the HPV genotypes. In the present study, HPV genotyping results were pooled for each sample for increased analytical sensitivity.
Coupling of oligonucleotide probes to polystyrene beads. 5Ј-amino-modified C-12-linked oligonucleotide probes were coupled to distinctly colored sets of a Signals given as net median fluorescence intensity (MFI) values, background values were subtracted and only positive reactions are shown. Specific signals are indicated in boldface. *, weak cross-reactivity, e.g., cross-reactivity of the HPV65 probe with HPV4 PCR products; †, weak cross-reactivity due to contaminations of type-specific probes during synthesis. carboxylated polystyrene beads (xMAP; Luminex Corp., Austin, TX) by a carbodiimide-based coupling procedure as described previously (27) .
McPG. Following the modified nested "hanging-droplet" FAP PCR amplification, 10 l of each reaction was analyzed by Luminex hybridization under conditions described elsewhere (27) .
Briefly, PCR products were denatured and hybridized to the bead-coupled probes in 96-well plates. After transfer into wash plates with filter bottoms, unhybridized DNA was removed. Subsequently, biotinylated PCR products were stained by streptavidin R-phycoerythrin conjugate. After further washing steps, beads were analyzed in a Luminex analyzer (Luminex Corp.), which contains two lasers to identify the bead set by the internal bead color and to quantify the reporter fluorescence on the bead. The results were expressed as the median fluorescence intensity (MFI) of at least 100 beads per set.
In one well per plate, a PCR product that showed a positive hybridization signal in previous experiments was used as positive control. For determination of the background (autofluorescence of each bead set and background reactions resulting from binding of streptavidin R-phycoerythrin to the probe-coupled beads), each plate contained at least two wells with 10 l of Tris-EDTA buffer instead of PCR product.
Cutoff definition. For each probe, the MFI values in hybridization reactions with TE buffer instead of PCR product were considered background. Net MFI values were calculated by subtraction of 1.2 times the probe-specific mean background value. Net MFI values above a cutoff of 5 MFI were defined as positive hybridization signals. Due to high background values, cutoffs were adjusted for HPV 8 and FA 5 (10 MFI) and HPV 92 (30 MFI). For all probes, these cutoff values were above the mean background plus three times the standard deviation. Nucleotide sequence accession numbers from GenBank. Nucleotide sequences of complete HPV genomes (n ϭ 42), of subgenomic FA fragments (n ϭ 133) and FA subtypes (n ϭ 45) were obtained from GenBank and used for primer and probe design. The accession numbers were obtained from Forslund et al. (12) .
RESULTS

Specificity of McPG.
Type-specific probes were hybridized to 10 l of PCR product of all 58 HPVs and FA amplicons derived from saturated PCR on bacterial colonies using the inner McPG primers (Table 1 ). All 58 analyzed HPVs and FA amplicons could be detected specifically. Due to variants found in the probe binding region of HPV96, two HPV96 probes were required for unequivocal type identification. From the 58 examined HPVs and FA probes, 41 reacted with absolute specificity. Eleven probes showed unspecific reactivities with one to six additional HPVs and/or FA amplicons (Table 1) . Unspecific signals could be excluded via an interpretation algorithm described elsewhere (29) . No cross-reaction between the HPVs and FA PCR products and the ␤-globin probe was observed.
Analytical sensitivity of McPG. The analytical sensitivity of McPG with integrated ␤-globin primers was tested for all 38 defined HPV types. A 10-fold dilution series of HPV plasmid DNA in a constant background of 100 ng of HP DNA was prepared for each of the 38 HPVs. Dilutions containing 1,000, 100, 10, or 1 plasmid copy were processed by PCR, and the products were analyzed by hybridization. The analytical sensitivity reached 1 to 10 plasmid copies per reaction for 35 HPVs and 100 plasmid copies for 3 of the 38 tested HPVs ( Table 2 ).
In the original protocol of Forslund et al. (13) , AmpliTaq Gold polymerase with buffer II (Roche) was used. The analytical sensitivity of McPG using a multiplex PCR kit (Qiagen) compared to AmpliTaq Gold was 10-to 1,000-fold improved for 29 types and remained identical for 7 types, and only 2 types were better amplified (1 copy instead of 10) using AmpliTaq Gold (data not shown).
␤-Globin primer integration. To allow internal DNA quality and PCR control, 0.1 M MS 3 and 5Ј biotinylated MS 10 primers (29) amplifying a 208-bp fragment of the ␤-globin gene were integrated in the nested FAP PCR. The analytical sensitivity of the ␤-globin PCR analyzed by 10 individually prepared 10-fold dilution series of HP DNA was Յ1 ng, which corresponds to Յ170 human cell equivalents (Fig. 1) .
Reproducibility a *, the worst detection limit of two PCRs is shown; †, three independent dilution series; worst detection limit of at least two PCRs is shown; ‡, two independent dilution series (the worst detection limit of two PCRs is shown); §, two probes are needed for unequivocal HPV96 identification.
b ND, species not yet determined.
showed partial agreement with at least one concordant HPV type detected, and 6 (11.1%) showed complete disagreement. Analytical sensitivity for multiple infections. Multiple infections were simulated by mixes of HPV plasmid DNA. Four mixes containing plasmid DNA of 5, 10, 15, and 20 different HPV types were prepared. Each mix was diluted in a background of 100 ng of HP DNA to 1,000, 100, 10, and 1 copy per HPV type. The MFI values for each HPV type present in the mix decreased with decreasing HPV plasmid copies, as well as with increasing numbers of additional HPV types, as shown, for example, for HPV1 and HPV4 (Fig. 2) . Compared to single infections, detection limits were ϳ10-fold higher for the 5-fold infections and 10-to 100-fold higher for 10-and 15-fold infections.
In analyses of the 15-fold infections, all 15 HPV types could be detected with 1,000 copies per PCR, and 14 types could be detected with 100 copies per PCR. In analyses of 20-fold infections, 17 HPV types could be detected both with 1,000 and 100 copies per PCR, while 3 HPV types (HPV23, HPV48, and HPV76) could not be detected with 1,000 copies/PCR. However, two of these three types (HPV23 and HPV48) also showed the highest detection limit of 100 copies/PCR in the singleplex PCR.
Comparison of McPG to original nested FAP PCR, followed by sequencing. Of 342 skin biopsy DNA samples from a hospital-based case-control study of NMSCs and premalignant and benign skin lesions. 14 were excluded from the analysis due to insufficient DNA material for McPG. In addition, 6 of the 342 DNA samples were HPV and ␤-globin negative by McPG and thus excluded due to poor DNA quality.
McPG was performed blindly in the remaining 322 DNA samples. In analyses of only the HPVs detectable by both methods, the overall DNA positivity was 33.2% by the pooled results from three original nested FAP PCR, followed by sequencing (i.e., nFAP-PCR sequencing) and 37.0% by McPG. Complete agreement between McPG and nFAP-PCR sequencing was found in 180 of the 322 (55.9%) samples, 170 (94.4%) of which were concordantly HPV negative. Ninety-six (56.5%) of the concordantly negative samples were from healthy skin. Partial agreement (at least one or more identical types were detected by both methods) was found in 46 (14.3%) cases. In 96 (29.8%) cases, the results were completely discordant.
Of the 25 HPV and FA types that were detected more than four times by any of the two methods, 15 and 7 distinct types were more clearly detected by McPG and nFAP-PCR sequencing, respectively (Fig. 3) . The biggest difference between the two assays in detecting specific types was found for HPV22, HPV37, FA1.1, and FA51, which could not be detected by nFAP-PCR sequencing. HPV types 5, 15, 17, 23, and 36 and FA14 were detected at least two times more frequently by McPG, and HPV93 was detected at least two times more frequently by nFAP-PCR sequencing.
The number of types per multiple HPV infection determined by McPG was higher (on average, 2. 
DISCUSSION
The natural history of the infection for cutaneous PVs, as well as their putative role in the development of NMSC, remain largely unknown. Cutaneous PVs do not form a separate clade and do not share a common ancestor. In addition, they seem to be ubiquitously detectable in the skin of virtually all mammals since very early after birth, although these PVs are present in very low copy numbers (2) . For these reasons, highly sensitive detection methods that cover a broad spectrum of HPVs are needed, and several PCR assays in combination with genotyping methods such as sequencing, RLB, RHA, and We describe here the development and validation of a novel bead-based multiplex genotyping assay, McPG, that allows for the simultaneous detection of 38 defined HPV types in the beta, gamma, mu, and nu PV genera, as well as of 20 FA amplicons putatively representing cutaneous HPVs yet to be described. The less closely related cutaneous HPVs of the alpha genus are included in a separate assay that is capable of genotyping all cutaneous HPVs of the alpha, mu, and nu genera (28) . McPG is characterized by a high analytical sensitivity, improved ability to detect multiple infections, and suitability in high-throughput analyses. Furthermore, an integrated ␤-globin PCR allows for internal DNA quality and PCR efficacy control.
McPG is composed of a nested PCR and genotyping by hybridization of the amplicons to type-specific probes coupled to fluorescently labeled polystyrene beads. The use of nested FAP PCR (12) for viral amplifications offers some advantages compared to other PCR systems. It amplifies not only known but also unknown and thus putative cutaneous HPVs. Having two PCR mixtures present in a single tube with the second PCR mixture present as hanging droplet in the lid avoids opening the tube between PCR rounds and thereby minimizes the risk of cross-contamination. The sensitivity as analyzed by plasmid dilutions and clinical samples is high, and the nested PCR products have an optimal length for genotyping by the Luminex technique. However, the nested FAP PCR exhibits some disadvantages. The amplifiable HPV spectrum is limited mainly to beta PVs due to mismatches of the primer pair FAP59/64 and the primer FAP6319R. To overcome this limitation, 18 additional McPG primers were included, thereby minimizing the number of mismatches and enabling the detection of all HPVs of the beta, gamma, mu, and nu genera.
The analytical sensitivity of McPG for the HPVs included is largely homogeneous under standardized experimental conditions, i.e., when analyzed with single HPV plasmid dilutions. However, it might vary in multiple infections in clinical samples, since HPV types may be present in different copy numbers. Due to competition for primers, polymerase, and deoxyribonucleoside triphosphates, HPV types with low viral loads might not be detected in each reaction, especially not when other types are present with higher copy numbers. As a consequence, the real HPV prevalence may be underestimated as also described for other PCR systems (30, 34) . In McPG, the risk for amplification bias by a dominant type is reduced by the addition of several type-specific primers. Thus, we consider McPG advantageous for analyzing multiple infections. This was demonstrated by the detection of up to 13 types in one clinical sample and the detection of up to 17 types in mixes of HPV plasmids.
McPG was compared to the original nested FAP PCR by analyzing 322 DNA samples extracted from cutaneous biopsy specimens previously analyzed by three individual laboratories performing the nested FAP PCR with subsequent sequencing (14) . To increase the analytical sensitivity, final genotyping results were pooled from all three laboratories (14) . HPV types not included in the McPG probe spectrum were excluded from the analysis. The comparison showed a complete or partial agreement in 70.2% of the clinical samples. We also obtained evidence for a higher analytical sensitivity of McPG, especially for detecting multiple HPV infections. The discordance in HPV results in these specimens could be due to a number of explanations. One is that HPV copy numbers are usually very low in the skin tissue and might not be detected in every PCR (35) . Another alternative view is the reduced sensitivity of sequencing compared to hybridization systems. While Ͼ10 ng of PCR products are required for sequencing, as little as 0.1 ng of PCR products can be detected by Luminex hybridization methods (27) . To circumvent this limitation, two of the laboratories cloned PCR products prior to sequencing; however, for practical reasons, only three clones per sample could be sequenced (14) . A third possibility, which may explain discordance in multiple infections is due to amplification competition between different HPV genotypes, especially when direct sequencing of PCR products is performed. We suppose that this effect is stronger for the conventional FAP primers than for the McPG primers.
A problem common to all cutaneous HPV genotyping assays is the fact that broad-spectrum primers can usually amplify more types than can be genotyped or sequenced subsequently. In addition, competition for primers by HPVs not included in the genotyping assay may reduce analytical sensitivity for other types. To date, no consensus exists on the cutaneous HPV's prevalence and type spectrum due to different primers and PCR systems being used in different studies. However, it is likely that each system underestimates the real HPV type spectrum in the skin. Consequently, more than one assay should be performed and additional HPVs should be continuously included in existing assays for a more accurate assessment of cutaneous HPVs. The McPG assay, which takes advantage of the Luminex hybridization system, is flexible enough for the integration of additional HPV type-specific probes. In theory, McPG allows extending the probe number to up to 100 per hybridization assay. However, the impact of adding additional probes on the analytical specificity needs to be investigated when introducing changes in the assay.
In summary, we describe here the development and validation of McPG. McPG is highly sensitive for genotyping a broad spectrum of cutaneous HPVs in a high-throughput fashion that could be used to investigate cutaneous HPVs in large epidemiological studies and might help to elucidate the role of HPV infections in skin diseases, such as NMSC.
